Hypoglycemic agents in the management of type 2 diabetes mellitus

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 1, 2011, Pages 66-73

  Ho, Josephine ^a   Leung, Alexander K C ^a   Rabi, Doreen ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hyperglycemia; Hypoglycemic agents; Pharmacotherapy; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLICLAZIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOKINASE; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PHOSPHODIESTERASE INHIBITOR; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REMOGLIFLOZIN ETABONATE; RIMONABANT; ROSIGLITAZONE; SERGLIFLOZIN ETABONATE; SULFONYLUREA DERIVATIVE;

ANXIETY; ARTICLE; C CELL HYPERPLASIA; CARDIOVASCULAR RISK; CELL HYPERPLASIA; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DEPRESSION; DIABETIC RETINOPATHY; DIARRHEA; DIET; DRUG HALF LIFE; EXERCISE; FLATULENCE; FRACTURE; GARLIC; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GERMANDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HEART INFARCTION; HERBAL MEDICINE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICINAL PLANT; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; POMEGRANATE; PRIORITY JOURNAL; RETINA MACULA EDEMA; SIDE EFFECT; SILYBUM MARIANUM; WATERMELON; WEIGHT REDUCTION;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC; PRACTICE GUIDELINES AS TOPIC;

EID: 79551632306     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411794351879     Document Type: Article

References (84)

1. Ho J, Pacaud D, Leung AK. Type 2 diabetes mellitus in children: A new challenge for diagnosis and prevention. Consultant Pediatr 2006; 5: 77-80.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
3. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005; 365(9467): 1333-46.
4. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005; 59(7): 365-73.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.
6. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-50.
7. Canadian Diabetes Association. Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(Suppl 1): S1-S201.
8. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193-203.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl 1): S62-9.
10. World Health Organization (WHO): Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. Geneva: World Health Organization 2006: 1-50.
11. Ansari G, Mojtahedzadeh M, Kajbaf F, Najafi A, Khajavi MR, Khalili H, et al. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 2008; 25(7): 681-702.
12. United Kingdom Prospective Diabetes Study (UKPDS) Group. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ Clin Res 1995; 310(6972): 83-8.
13. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352(9131): 854-65.
14. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334(9): 574-79.
15. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metabol 1996; 81(11): 4059-67.
16. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metabol 2003; 29(4 Pt 2): 6S71-76.
17. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33(6): 1304-8.
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (Online) 2010; 4: CD002967.
19. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: Systematic review and meta-analysis. Arch Intern Med 2003; 163(21): 2594-602.
20. Mojtahedzadeh M, Rouini MR, Kajbaf F, Najafi A, Ansari G, Gholipour A, et al. Advantage of adjunct metformin and insulin therapy in the management of glycemia in critically ill patients. Evidence for the nonoccurrence of lactic acidosis and needing to parenteral metformin. Arch Med Sci 2008; 4(2): 174-81.
21. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64(12): 1339-58.
22. Salsburg DS. The UGDP study. JAMA 1971; 218(11): 1704-5.
23. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352(9131): 837-53.
24. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009; 32(11): 2068-74.
25. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: An international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data. Study to Prevent Non-Insulin- Dependent Diabetes Mellitus. Diabetes Care 1998; 21(10): 1720-5.
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290(4): 486-94.
27. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106-18.
28. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004; 26(2): 177-90.
29. Einhorn D, Aroda VR, Henry RR. Glitazones and the management of insulin resistance: What they do and how might they be used. Endo Met Clin North Am 2004; 33(3): 595-616.
30. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.
31. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007; 298(10): 1189-95.
32. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Syst Rev (Online) 2007; (3): CD006063.
33. Dahabreh IJ, Economopoulos K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5(2): 116-20.
34. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 2007; 357(1): 28-38.
35. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125-35.
36. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA Warning - Geographic Variation in the Use of Rosiglitazone. N Engl J Med 2010; [Epub ahead of print].
37. Feng, J., Gwaltney, I., Kaldor, S.W., Stafford, J.A., Wallace, M.B., Zhang, Z. US7790736 (2010).
38. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutidethe FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362(9): 774-7.
39. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care 2009; 32(5): 834-8.
40. Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48(5): 838-48.
41. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Hormone Metab Res 2002; 34(9): 504-8.
42. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005; 27(10): 1500-12.
43. Ikenoue, T., Kageyama, Y., Iino, Y., Kondo, N. Therapeutic agents for diabetes. US7807663 (2010).
44. Shimada, T., Ueno, H., Tsutsumi, K., Aoyagi, K., Manabe, T., Sasaki, S.Y., Katoh S. Spiro-ring compound and use thereof for medical purposes. EP2202216 (2010).
45. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Investig 2002; 110(6): 851-60.
46. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008; 149(5): 2208-18.
47. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Eng J Med 2007; 356(15): 1517-26.
48. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32(9): 1663-8.
49. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metabol 2010; 95(1): 34-42.
50. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111(6): 544-7.
51. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14(11): 2873-82.
52. Neumiller JJ, White JR, Jr., Campbell RK. Sodium-glucose cotransport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70(4): 377-85.
53. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al. Sergliflozin, a novel selective inhibitor of lowaffinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320(1): 323-30.
54. Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50(6): 623-35.
55. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32(4): 650-7.
56. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32(9): 1656-62.
57. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327(1): 268276.
58. Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res 2007; 21(4): 535-53.
59. Scheen AJ. The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 2009; 10(1): 56-74.
60. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 2009; 61(2): 217-24.
61. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metabol 2007; 33(2): 85-95.
62. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1- year experience from the RIO-Europe study. Lancet 2005; 365(9468): 1389-97.
63. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006; 295(7): 761-75.
64. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368(9548): 1660-72.
65. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A metaanalysis of randomised trials. Lancet 2007; 370(9600): 1706-13.
66. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet 2007; 370(9600): 1671-2.
67. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Investig 2010; 120(8): 2953-66.
68. Patti ME. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? J Clin Investig 2010; 120(8): 2646-48.
69. Zhang L, Liu H. Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and G(L)-subunit of glycogen-associated protein phosphatase 1: WO2009127723. Expert Opin Ther Pat 2010; 20(6): 1-5.
70. Langkopf, E., Himmelsbach, F., Mack, J., Pautsch, A., Schoelch, C., Schuler-Metz, A., Streicher, R., Wagner, H. New arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments. WO2009127723 (2009).
71. Zibrova D, Grempler R, Streicher R, Kauschke SG. Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes. Biochem J 2008; 412(2): 359-66.
72. Polakof S. Diabetes therapy: novel patents targeting the glucoseinduced insulin secretion. Recent Pat DNA Gene Seq 2010; 4(1): 1-9.
73. Shi, Y., Cheng, P., Wang, Y., Ryono, D. Novel glucokinase activators and methods of using the same. US2009030046 (2009). & EP2173717 (2010).
74. Ryono, D.E., Cheng, P.T.W., Bolton, S.A., Chen, S.S., Shi, Y., Meng, W., Tino, J.A., Zhang, H., Sulsky, R.B. Novel glucokinase activators and methods of using the same. ZA0810757 (2010).
75. Shi, Y., Cheng, P.T.W., Wang, Y., Ryono, D.E. Glucokinase activators and methods of using the same. US7812048 (2010).
76. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev 2009; 8(5): 399-416.
77. Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55(1): 1-12.
78. Yu LF, Qiu BY, Nan FJ, Li J. AMPK activators as novel therapeutics for type 2 diabetes. Curr Top Med Chem 10(4): 397-410.
79. Pugazhenthi U, Velmurugan K, Tran A, Mahaffey G, Pugazhenthi S. Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: Potential therapeutic benefits in diabetic patients. Diabetologia 2010; 53(11): 2357-68.
80. Liang L, Beshay E, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 1998; 47(4): 570-5.
81. Rabinovitch A, Sumoski WL. Theophylline protects against diabetes in BB rats and potentiates cyclosporine protection. Diabetologia 1990; 33(8): 506-8.
82. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arch Med Sci 2008; 4(3): 285-92.
83. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidantrelated diseases. Inflamm Allergy Drug Targets 2009; 8(1): 2-10.
84. Lexi-Comp Online http: //online.lexi.com, Lexi-Comp, Inc., Hudson, Ohio, USA 2010.